Choi Boomin, Ahn Min-Hye, Hong Seojin, Barcelon Ellane Eda, Sangshetti Jaiprakash, Arote Rohidas B, Lee Sung Joong
Department of Neuroscience and Physiology, Dental Research Institute, School of Dentistry, Seoul National University Seoul 08826 Republic of Korea
Department of Molecular Genetics and Dental Research Institute, School of Dentistry, Seoul National University Seoul 08826 Republic of Korea
RSC Adv. 2021 Nov 16;11(58):36792-36800. doi: 10.1039/d1ra06277h. eCollection 2021 Nov 10.
Recent progress in personalized medicine and gene delivery has created exciting opportunities in therapeutics for central nervous system (CNS) disorders. Despite the interest in gene-based therapies, successful delivery of nucleic acids for treatment of CNS disorders faces major challenges. Here we report the facile synthesis of a novel, biodegradable, microglia-targeting polyester amine (PEA) carrier based on hydrophilic triethylene glycol dimethacrylate (TG) and low-molecular weight polyethylenimine (LMW-PEI). This nanocarrier, TG-branched PEI (TGP), successfully condensed double-stranded DNA into a size smaller than 200 nm. TGP nanoplexes were nontoxic in primary mixed glial cells and showed elevated transfection efficiency compared with PEI-25K and lipofector-EZ. After intrathecal and intracranial administration, PEA nanoplexes delivered genes specifically to microglia in the spinal cord and brain, respectively, proposing TGP as a novel microglia-specific gene delivery nanocarrier. The microglia-specific targeting of the TGP nanocarrier offers a new therapeutic strategy to modulate CNS disorders involving aberrant microglia activation while minimizing off-target side effects.
个性化医疗和基因递送领域的最新进展为中枢神经系统(CNS)疾病的治疗带来了令人兴奋的机遇。尽管基于基因的疗法备受关注,但成功递送核酸用于治疗CNS疾病仍面临重大挑战。在此,我们报告了一种基于亲水性二甲基丙烯酸三甘醇酯(TG)和低分子量聚乙烯亚胺(LMW-PEI)的新型可生物降解的靶向小胶质细胞的聚酯胺(PEA)载体的简便合成方法。这种纳米载体,即TG支化的PEI(TGP),成功地将双链DNA浓缩成小于200 nm的尺寸。TGP纳米复合物在原代混合胶质细胞中无毒,并且与PEI-25K和脂质转染试剂-EZ相比,转染效率更高。经鞘内和颅内给药后,PEA纳米复合物分别将基因特异性递送至脊髓和大脑中的小胶质细胞,表明TGP是一种新型的小胶质细胞特异性基因递送纳米载体。TGP纳米载体的小胶质细胞特异性靶向提供了一种新的治疗策略,可调节涉及异常小胶质细胞激活的CNS疾病,同时将脱靶副作用降至最低。